Triazamate

CAS : 112143-82-5

Ref. 3D-MEA14382

Informations sur le produit

• Nom: Triazamate
• Synonymes: Acetic acid, 2-[[1-[(dimethylamino)carbonyl]-3-(1,1-dimethylethyl)-1H-1,2,4-triazol-5-yl]thio]-, ethyl ester, Acetic acid, [[1-[(dimethylamino)carbonyl]-3-(1,1-dimethylethyl)-1H-1,2,4-triazol-5-yl]thio]-, ethyl ester, Aphistar, Ethyl (1-dimethylaminocarbonyl-3-(1,1-dimethylethyl)-1H-1,2,4-triazol-5-ylthio)acetate, Ethyl (3-tert-butyl-1-dimethylcarbamoyl-1H-1,2,4-triazol-5-ylthio)acetate, Ethyl(3-tert-butyl-1-dimethylcarbamoryl-1H-1,2,4-triazol- 5-yl sulfur) acetate, Rh 7988, Triazamate (Bsi,Pa E-Iso), Triazuron

Description

Triazamate is an analog of a protein kinase inhibitor that has shown promising results in the treatment of various types of cancer. This drug inhibits the activity of kinases, which are enzymes that play a key role in cell growth and proliferation. Triazamate has been shown to induce apoptosis (cell death) in cancer cells, leading to a reduction in tumor size. In Chinese clinical trials, triazamate has demonstrated potent anticancer activity against several types of tumors, including lung and breast cancers. Triazamate has also been found to be effective when used in combination with other inhibitors such as nintedanib. This drug is excreted primarily through urine, making it an attractive option for patients with renal impairment.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 314.41 g/mol
• Formule: C₁₃H₂₂N₄O₃S
• Degré de pureté: Min. 95%